论文部分内容阅读
维甲酸综合征常发生于应用维甲酸(ATRA)治疗急性早幼粒细胞白血病(APL)过程中,是危及生命的并发症,其发病机理尚未阐明。迄今为止未见大样本的详细报告。在一项正在进行的研究中,Botton等分析了413例初治的APL。在此研究中,年龄≤65岁,初发病时WBC<5000/μl的病人被随机分成两组,分别采用ATRA诱导后化疗(一组:ATRA→CT)或ATRA诱导同时在第3天开始化疗(二组)。在初发病时WBC≥5000/μl,同时接受ATRA和化疗。年龄在66～75岁之间者接受ATRA诱导后化疗。在初始WBC<5,000/μl并采用ATRA→CT方案组,ATRA诱导的第5,10,15天若白细胞数分别大于6,000/μl、10,000/μl、15,000/μl,立即采用化疗(DNR60mg/m~2/d×3天,
Retinoic acid syndrome often occurs in the treatment of acute promyelocytic leukemia (APL) with retinoic acid (ATRA). It is a life-threatening complication and its pathogenesis has not yet been elucidated. No detailed report has been found so far. In an ongoing study, Botton et al. analyzed 413 previously untreated APLs. In this study, patients aged ≤ 65 years and having a WBC of <5000/μl at the time of initial onset were randomly divided into two groups. They were treated with ATRA-induced chemotherapy (group ATRA → CT) or ATRA induction and started on the third day. (Second group). At the time of first onset WBC ≥ 5000/μl, receiving both ATRA and chemotherapy. People between the ages of 66 and 75 received chemotherapy induced by ATRA. In the initial WBC<5,000/μl and ATRA→CT regimen group, ATRA induced on day 5, 10, and 15 if the number of leukocytes was greater than 6,000/μl, 10,000/μl, and 15,000/μl respectively, chemotherapy was immediately used (DNR 60 mg/m~ 2/d×3 days,